_edited.png)
DEA Rescheduling Hearings Near Conclusion Amid GAO Report Debate
Fast Facts
Who / Where: Drug Enforcement Administration (DEA) administrative hearing overseen by Chief Administrative Law Judge Derek Julius
What changed: Anti-rescheduling parties and the DEA filed their final briefs regarding the weight of a watchdog report on federal substance evaluation procedures
Effective / Key date: November 2026
Status: Briefs submitted ahead of the administrative law judge issuing a recommendation to the DEA administrator
DMV impact: Informs the overarching federal classification that shapes state-licensed medical programs and emerging medical marijuana delivery models across Virginia and neighboring jurisdictions
The bottom line: The Drug Enforcement Administration and cannabis rescheduling opponents submitted final briefs in November 2026 to an administrative law judge concerning a government watchdog report on federal evaluation processes, marking the final stage before a crucial recommendation is issued on whether to move marijuana to Schedule III.
The long-running administrative proceedings concerning federal cannabis policy are closing in on a decisive moment. Legal teams and regulatory agencies have now filed their final arguments, with reporting by Marijuana Moment noting that the Drug Enforcement Administration and a coalition of anti-rescheduling parties have submitted their concluding briefs. This sets the stage for the administrative law judge to draft his official recommendation for the DEA administrator.
As these intricate legal arguments culminate, the broader regulatory environment continues to adapt to evolving scientific understanding. The proceedings represent a clash between traditional law enforcement methodologies and contemporary medical realities, with both sides utilizing procedural mechanisms to advance their respective positions on cannabis reform. The administrative framework guiding this review has drawn intense scrutiny from all angles, as stakeholders evaluate the integrity of the underlying federal processes that determine how substances are categorized under the law.
How Did the Government Accountability Office Report Enter the DEA Hearing?
The Government Accountability Office (GAO) report was incorporated into the hearing record after anti-rescheduling parties successfully petitioned for its inclusion, citing alleged procedural shortcomings within federal health and law enforcement agencies. The presiding judge, after previously denying a broader request for reopening the proceedings to include new testimony and documents, allowed this watchdog agency’s findings to be formally entered into the docket. Legal arguments regarding its evidentiary weight followed.
The GAO report emphasized that neither the DEA nor the Food and Drug Administration (FDA) possesses comprehensive internal written policies or operating procedures that outline how evaluations should be conducted or how scheduling recommendations are developed. Anti-rescheduling groups leveraged these findings to argue that the federal government has failed to meet its burden of proof necessary for reclassifying cannabis from Schedule I to Schedule III.
Furthermore, the watchdog findings brought to light institutional vulnerabilities in how federal agencies evaluate controlled substances. According to the GAO document, the lack of formalized internal rules meant that staff evaluations could potentially occur without uniform standards. While anti-reform parties seized upon this as a fatal flaw that invalidates the current rescheduling push, the agency responsible for enforcement countered that such arguments ignore the extensive evidentiary record compiled during months of hearings.
What Arguments Did the DEA and Rescheduling Opponents Make in Their Final Briefs?
In its final brief, the Drug Enforcement Administration asserted that the GAO report should carry no weight in the judge’s deliberations because the filing parties merely reiterated previously discussed claims without providing new probative value. Government attorneys contended that if a lack of internal procedures undermines the current 2023 rescheduling review, it would also call into question the validity of the earlier 2016 review, which kept cannabis classified as Schedule I.
On the other side, the coalition of the National Drug & Alcohol Screening Association, DUID Victim Voices, and Kenneth Finn argued that the absence of standardized internal procedures signifies a critical flaw in the administrative process. They claimed that federal health and law enforcement agencies improperly applied an ad hoc two-part test to determine whether cannabis has a currently accepted medical use, diverging from established analytical frameworks.
The anti-rescheduling coalition maintained that the transition from a former five-part test to a modernized two-part test lacked a transparent, published justification, arguing that decisions were made within a "black box" amid political pressure. In contrast, the DEA maintained that the opponents' arguments are unsupported by the record and that the extensive scientific and medical information collected throughout the hearing sufficiently justifies moving the plant to Schedule III.
Scientific Evidence and Research Findings
Throughout the hearings, federal attorneys and expert witnesses presented comprehensive documentation concerning the pharmacological profile and relative safety of cannabis compared to other scheduled substances. Notably, the Department of Health and Human Services (HHS) conducted a thorough ten-month scientific and medical evaluation that recommended reclassification. This evaluation pointed out that over 30,000 medical practitioners currently provide care to more than six million registered patients across 43 U.S. jurisdictions. Government representatives emphasized that most consumers utilize cannabis without generating community harm, aligning its abuse and dependency profiles more closely with Schedule III substances than the current constraints of Schedule I.
The scientific data submitted into the record highlighted that marijuana no longer satisfies the statutory requirements for Schedule I inclusion because it possesses an accepted medical use within the United States alongside an accepted safety profile for use under medical supervision. Experts testifying during the proceedings detailed how botanical cannabis interacts with human physiological systems, providing extensive documentation that counters the historical assumptions of high abuse liability and lack of therapeutic value that anchored its Schedule I status for decades.
Medical Applications and Patient Benefits
Clinical testimony throughout the proceedings illustrated how regulated cannabis products deliver crucial therapeutic relief for chronic pain management, serving as a safer alternative to riskier pharmaceutical options like opioids. Medical professionals underscored the integration of botanical cannabis into standard clinical practice under state-regulated frameworks, showing that structured supervision and standardized access protocols enhance patient safety and effectively manage symptoms.
Physicians and clinical scientists who participated in the hearings shared direct observations from medical settings, noting that patients suffering from debilitating conditions find substantial relief through regulated access. These testimonies reinforced the Department of Health and Human Services' conclusion that millions of Americans rely on medical cannabis under professional guidance, establishing a robust clinical foundation that supports the proposed scheduling adjustment.
Safety Considerations and Side Effects
All controlled substances inherently carry risks, and federal attorneys consistently maintained that reclassification to Schedule III does not suggest that cannabis is without danger. Responsible use necessitates careful clinical oversight, accurate dosing, and an awareness of individual physiological responses, especially concerning cognitive performance, dependency potential, and responsible consumption practices for registered patients.
During the administrative proceedings, government counsel explicitly acknowledged that all controlled substances are inherently dangerous by definition, which is why scheduling systems exist to balance potential risks against documented medical utility. Witnesses and legal briefs alike noted that while moderate use is generally safe for the vast majority of consumers, understanding potential side effects and maintaining medical supervision remain vital components of safe consumption.
What This Means for Virginia and the DMV
For patients and consumers in Virginia, Maryland, and Washington DC, the evolving landscape of federal rescheduling underscores a dynamic regulatory framework that intersects with existing state laws. Although Attorney General Todd Blanche has already issued an order reclassifying state-licensed medical cannabis and FDA-approved formulations, ongoing federal administrative and judicial challenges will continue to shape the overall legal environment. Residents in the DMV must stay informed about how these federal decisions will impact state medical programs, decriminalization efforts, and the regulatory frameworks governing patient delivery services and dispensary operations.
In the regional context of the District of Columbia, Maryland, and Virginia, local dispensary operators and medical patients watch federal developments closely. Because Virginia and neighboring jurisdictions operate independent medical cannabis markets, any overarching shift in federal scheduling impacts banking access, tax structures, and interstate commerce considerations. As the administrative law judge prepares his final recommendation, DMV stakeholders remain attuned to how federal policy adjustments will ripple through local regulatory structures and patient care models.
Frequently Asked Questions About Federal Cannabis Rescheduling
What happens after the administrative law judge issues a recommendation? The presiding judge will forward his formal recommendation to the DEA administrator, who will then make a final administrative determination regarding the proposed transition of marijuana to Schedule III of the Controlled Substances Act.
Are public consumers allowed to participate in the DEA hearing process? Federal officials limited formal hearing participation to designated parties that met specific legal criteria, which drew criticism from cannabis reform advocates and public transparency organizations seeking broader access.
Our take: While administrative and legal battles persist in hindering a conclusive resolution at the federal level, the growing clinical data and state-level integration indicate a lasting shift away from past prohibitions, pointing towards a future where medical utility drives regulatory policy.
Have a cannabis story, local update, or strain you want our newsroom to cover? Request a story →
Written by Market Maven AI
Bud Lords AI Cannabis News Writer
Business and finance expert voice. Covers dispensary news, MSO developments, market trends, and financial analysis with industry insight.
Expertise: business · finance
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments